WO2016206363A1 - Utilisation d'oligopeptide de ginseng de jilin dans la préparation d'un produit alimentaire anti-oxydant ou d'un produit alimentaire de soins de santé - Google Patents

Utilisation d'oligopeptide de ginseng de jilin dans la préparation d'un produit alimentaire anti-oxydant ou d'un produit alimentaire de soins de santé Download PDF

Info

Publication number
WO2016206363A1
WO2016206363A1 PCT/CN2016/070592 CN2016070592W WO2016206363A1 WO 2016206363 A1 WO2016206363 A1 WO 2016206363A1 CN 2016070592 W CN2016070592 W CN 2016070592W WO 2016206363 A1 WO2016206363 A1 WO 2016206363A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginseng
jilin
food product
oligopeptide
control group
Prior art date
Application number
PCT/CN2016/070592
Other languages
English (en)
Chinese (zh)
Inventor
李勇
王军波
石丰
Original Assignee
吉林肽谷生物工程有限责任公司
李勇
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 吉林肽谷生物工程有限责任公司, 李勇 filed Critical 吉林肽谷生物工程有限责任公司
Publication of WO2016206363A1 publication Critical patent/WO2016206363A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)

Definitions

  • the invention relates to a new use of Jilin ginseng oligopeptide, in particular to the use of Jilin ginseng oligopeptide in anti-oxidation function food or health food.
  • Oxidative Stress refers to the excessive production of high activity molecules such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the body when subjected to various harmful stimuli.
  • ROS reactive oxygen species
  • RNS reactive nitrogen species
  • the degree of oxidation exceeds the removal of oxides, and the oxidative system and the antioxidant system are unbalanced, resulting in damage to biological cells such as tissues and proteins and nucleic acids.
  • the main anti-oxidation drugs for clinical use include monoamine oxidase inhibitors, dopamine receptor agonists, and vitamins. These drugs have varying degrees of side effects and should not be taken for long periods of time. Numerous studies in recent years have confirmed that natural food ingredients are safe and effective in terms of antioxidants.
  • a bioactive peptide refers to a peptide compound that is beneficial or physiologically active to the living activities of a living organism.
  • Peptides are intermediate in amino acid and protein in molecular structure, but they have functions that cannot be replaced by amino acids and proteins.
  • Oligopeptides also known as active small molecule peptides, generally consist of 10 or fewer amino acids. Studies have found that oligopeptides are more effective than single amino acid absorption and can directly participate in protein synthesis, thus improving the body's protein utilization. In the case of obstacles in the amino acid transport system, the ingestion of oligopeptides can achieve good absorption.
  • bioactive peptides have a wide range of biological activities, such as immune regulation, cholesterol lowering, blood pressure lowering, antithrombotic, anti-cancer, anti-viral, anti-oxidation and scavenging free radicals, and promote growth.
  • bioactive peptides have emerged with their high efficiency and safety, and gradually show their important role in clinical nutrition and broad application prospects.
  • Ginseng is a valuable Chinese herbal medicine.
  • the medicinal use of ginseng has been more than 4,000 years old.
  • the ginseng of our country is the dry root and rhizome of the ginseng of the Araliaceae plant, which is mainly produced in Jilin province.
  • the Chinese Ministry of Health approved ginseng as a new resource food.
  • Ginseng has the effects of replenishing vitality, quenching thirst, and calming the nerves.
  • MDA malondialdehyde
  • antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Play an antioxidant role.
  • SOD superoxide dismutase
  • GSH-Px glutathione peroxidase
  • ginseng oligopeptides exist as an important class of compounds in ginseng tissues, their functional studies have not been reported, and studies on their antioxidant functions have not been reported.
  • the ginseng oligopeptide is easily digested and absorbed in the human gastrointestinal tract, thereby avoiding waste of the active substance and greatly improving its biological activity, and can be used as a novel formula for food or health care products having an antioxidant function.
  • the object of the present invention is to provide a low-viscosity, easily absorbed and fast-absorbing Jilin ginseng oligopeptide in the preparation of antioxidant functional foods or health foods, and provides a new way for improving antioxidant function through diet.
  • the foods described therein are powders, tablets, liquid beverages, milk powder and dairy products, confectionery or baked goods.
  • the health food described therein is a powder, a tablet, a capsule or an oral liquid.
  • the invention finds that the existing substance-Jilin ginseng oligopeptide has anti-oxidation function and finds that it is preparing antioxidant activity. Use in energy or health foods. Animal experiments have found that the ginseng oligopeptide aqueous solution of Jilin ginseng can effectively improve the antioxidant function of oxidized model rats.
  • Jilin ginseng oligopeptide provided by Jilin Peptide Bioengineering Co., Ltd., light yellow solid powder
  • the main component is a small molecule oligopeptide with molecular weight less than 1000, the content is 97.4%.
  • mice 90 healthy adult SPF adult male SD rats, at the end of the adaptation period, weighing 200 ⁇ 20 g, provided by the Experimental Animal Center of Peking University Medical School. The experimental animals were kept in cages, 3 per cage, free to eat and drink. The animal breeding laboratory meets the national standard SPF level, the temperature range is 22 ⁇ 2°C, the relative humidity is 50% ⁇ 60%, and the nighttime alternation time is 12h:12h.
  • 3 dose grouping and test sample administration time 6 dose groups (0.0625g/kg BW, 0.125g/kg BW, 0.25g/kg BW, 0.50g/kg BW, 1.00g/kg BW, 2.00g) /kg BW), 1 blank control group, 1 whey protein group (0.25 g/kg BW) and 1 model control group.
  • the test sample was given for 45 days.
  • Rats were fed with basic diet for 5-7 days under the barrier system.
  • the blank control group was intraperitoneally injected with sterile physiological saline daily, and the injection amount was 0.2 mL/100 g once a day.
  • the model group was intraperitoneally injected with D-galactose 125 mg/kg BW, and the injection volume was 0.2 mL/100 g (31.25 g of D-galactose was dissolved in 500 ml of physiological saline to prepare D-galactose-sodium chloride injection. Before use, routine sterilization was used), once a day, continuous modeling for 6 weeks, blood MDA was taken, grouped according to MDA level, randomly divided into 1 model control group, 1 whey protein group and 6 recipients. Test sample dose group.
  • the six dose groups were intragastrically administered with different concentrations of ginseng peptide, the blank control group and the model control group were given the same volume of distilled water, and the whey protein group was given the same volume of whey protein aqueous solution.
  • the model control group, the whey protein group and each dose group continued to give the same dose of D-galactose intraperitoneal injection, and the blank control group continued to give the same dose of normal saline intraperitoneal injection.
  • each mouse was weighed once a week, and the amount of intraperitoneal injection and the amount of gastric perfusion were adjusted according to the body mass. The skin color, diet, drinking water, defecation, and mental activity of the rats were observed daily.
  • the rats were fasted for 12 hours after the water was fasted, and the rats were killed by decapitation.
  • the blood was centrifuged at 3000 r/min for 10 min, and serum was taken according to the kit instructions.
  • 8-Hydroxy-isoprostane (8-Isoprostane), malondialdehyde (MDA), protein carbonyl, superoxide dismutase (SOD), glutathione Glycopeptide peroxidase (GSH-Px), reduced glutathione (GSH) levels.
  • the liver was peeled off in an ice bath, the adipose tissue was removed, the tissue was rinsed with pre-cooled physiological saline until no blood color, and the same amount of tissue was weighed.
  • the tissue block was cut with ophthalmic scissors, and the corresponding multiple pre-cooled physiological saline was added to homogenate.
  • the mechanism is to test the required percentage (10%) of tissue homogenate (homogenization time 10s / time, interval 30s, in an ice bath), 3000r / min cryoprecipitate for 10min, take the supernatant, according to the kit instructions Determination of malondialdehyde (MDA), protein carbonyl, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and reduced glutathione (GSH) content.
  • MDA malondialdehyde
  • SOD superoxide dismutase
  • GSH-Px glutathione peroxidase
  • GSH reduced glutathione
  • the serum 8-epoxyisoprostane level of the ginseng oligopeptide C and D dose groups was significantly decreased (p ⁇ 0.05); the Jilin ginseng oligopeptide A, B, D, F doses
  • the serum malondialdehyde level of the rats in the group was significantly decreased (p ⁇ 0.05); the malondialdehyde level in the liver of the ginseng oligopeptide A, B, D and F groups was significantly decreased (p ⁇ 0.05).
  • the whey protein group there was no significant change in serum 8-epihydroxyisoprostane levels in the rats of Jilin ginseng oligopeptide. The difference was not statistically significant (p>0.05).
  • Jilin ginseng oligopeptide A The levels of serum malondialdehyde in rats in groups B, D and F were significantly lower (p ⁇ 0.05). The levels of malondialdehyde in the liver of Jilin ginseng oligopeptide F group were significantly lower (p ⁇ 0.05).
  • the serum protein carbonyl level of the model control group was significantly increased, and the difference was statistically significant (p ⁇ 0.05).
  • serum carbonyl levels in the whey protein group and Jilin ginseng oligopeptide A, B, C, D and E dose groups were significantly lower (p ⁇ 0.05); Jilin ginseng oligopeptide F dose group
  • Rat liver protein carbonyl levels were significantly increased (p ⁇ 0.05).
  • the serum and liver protein carbonyl levels of the Jilin ginseng oligopeptide F dose group were significantly increased (p ⁇ 0.05).
  • the serum and liver superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) levels in the model control group were absent. Significant changes, the difference was not statistically significant (p>0.05).
  • the serum SOD level of the ginseng oligopeptide C and E dose groups was significantly increased (p ⁇ 0.05); the Jilin ginseng oligopeptide B, C, D, F dose group had significant liver SOD levels.
  • the increase was (p ⁇ 0.05); the GSH-Px level in the liver of Jilin ginseng oligopeptide B, D, F dose group was significantly increased (p ⁇ 0.05); compared with the whey protein group, Jilin ginseng oligopeptide E dose group The serum SOD level in rats was significantly increased (p ⁇ 0.05); the serum GSH-Px levels in rats with ginseng oligopeptides A, B, C and F were significantly increased (p ⁇ 0.05); Jilin ginseng oligopeptides B, C, The liver SOD levels in the D and F dose groups were significantly increased (p ⁇ 0.05).
  • the serum GSH level of the ginseng oligopeptide B and C dose groups was significantly increased (p ⁇ 0.05); the liver GSH level of the Jilin ginseng oligopeptide C dose group was significantly increased (p ⁇ 0.05). There was no significant change in the other groups, and the difference was not statistically significant (p>0.05).
  • serum 8-epoxyisoprostane levels, serum and liver malondialdehyde (MDA) levels, serum protein carbonyl levels, and liver superoxide disproportionation were increased in the model control group compared with the blank control group.
  • the level of enzyme (SOD) was decreased, and the serum malondialdehyde (MDA) and protein carbonyl levels were the most significant, indicating that the experimental oxidation model was successfully established.
  • Jilin ginseng oligopeptides can significantly reduce the levels of lipid oxidation products and protein oxidation products in rats, increase the activity of antioxidant enzymes in rats, and thus exert antioxidant function, and have potential as a new antioxidant functional preparation.
  • the suitable concentration range is from 0.0625 to 1 g/kg bw per day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne l'utilisation d'un oligopeptide de ginseng de Jilin dans la préparation d'un produit alimentaire anti-oxydant ou d'un produit alimentaire de soins de santé.
PCT/CN2016/070592 2015-06-26 2016-01-11 Utilisation d'oligopeptide de ginseng de jilin dans la préparation d'un produit alimentaire anti-oxydant ou d'un produit alimentaire de soins de santé WO2016206363A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510357188.XA CN106259940A (zh) 2015-06-26 2015-06-26 吉林人参低聚肽在制备抗氧化功能的食品或保健食品中的用途
CN201510357188.X 2015-06-26

Publications (1)

Publication Number Publication Date
WO2016206363A1 true WO2016206363A1 (fr) 2016-12-29

Family

ID=57584518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/070592 WO2016206363A1 (fr) 2015-06-26 2016-01-11 Utilisation d'oligopeptide de ginseng de jilin dans la préparation d'un produit alimentaire anti-oxydant ou d'un produit alimentaire de soins de santé

Country Status (2)

Country Link
CN (1) CN106259940A (fr)
WO (1) WO2016206363A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110338429A (zh) * 2019-07-04 2019-10-18 山东薇薇朵生物科技有限公司 人参低聚肽在制备抗氧化功能的食品或保健食品中的用途
CN113892653A (zh) * 2021-10-27 2022-01-07 国药肽谷有限公司 人参肽在制备延缓血管系统衰老的食品或保健食品的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101824455A (zh) * 2009-03-06 2010-09-08 香港百特有限公司 一种大豆蛋白低聚肽及其制备方法和用途
CN103704830A (zh) * 2013-11-26 2014-04-09 天基神元生物科技（大连）有限公司 纳豆菌发酵法制备低分子人参皂苷肽的方法
CN104164466A (zh) * 2014-06-27 2014-11-26 宗树伟 一种人参肽的提取方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1785054A (zh) * 2005-11-25 2006-06-14 南京中科集团有限公司 一种具有抗氧化功能的保健食品及其制备工艺
CN102198195A (zh) * 2011-05-25 2011-09-28 遵义陆圣康源科技开发有限责任公司 一种具有抗氧化功能的药物组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101824455A (zh) * 2009-03-06 2010-09-08 香港百特有限公司 一种大豆蛋白低聚肽及其制备方法和用途
CN103704830A (zh) * 2013-11-26 2014-04-09 天基神元生物科技（大连）有限公司 纳豆菌发酵法制备低分子人参皂苷肽的方法
CN104164466A (zh) * 2014-06-27 2014-11-26 宗树伟 一种人参肽的提取方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FAN, JINJUAN ET AL.: "Research progress on oligopeptides derived from plant protein", FOOD SCIENCE AND TECHNOLOGY, vol. 34, no. 7, 20 July 2009 (2009-07-20) *
LU , QI ET AL.: "Review on the Studies of Micro-Guantitive Constituents in Panax Ginseng C. A. Meyer", GINSENG RESEARCH, 15 May 1994 (1994-05-15), pages 7 - 13 *
REN, WEI ET AL.: "Antioxidant Activity of Food-derived Peptides", FOOD AND FERMENTATION INDUSTRIES, vol. 34, no. 12, 30 December 2008 (2008-12-30), pages 44 - 46 *

Also Published As

Publication number Publication date
CN106259940A (zh) 2017-01-04

Similar Documents

Publication Publication Date Title
CA3014897C (fr) Soutien nutritionnel d'animaux par administration d'un supplement a base d'algues
TWI516280B (zh) 紅藜萃取物用於製備促進膠原蛋白生成及抗皮膚老化之組合物之用途
JP6684966B2 (ja) 新規なラクトバチルス・サケイ及びそれを含む組成物
BRPI0709083A2 (pt) composições que compreendem porphyra e métodos de preparação e utilização destas
KR20120097516A (ko) 고지혈증 개선제 및 빈혈 개선 조성물, 요산치 저하 조성물 및 음식품
TWI830696B (zh) 抑制肌纖維變性用組成物
WO2016141775A1 (fr) Utilisations d'oligopeptide de ginseng de jilin dans la préparation d'un produit alimentaire ou d'un produit alimentaire de santé pour combattre la fatigue
JP2018070570A (ja) クロモジ抽出物
KR20160141027A (ko) 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품
WO2016206363A1 (fr) Utilisation d'oligopeptide de ginseng de jilin dans la préparation d'un produit alimentaire anti-oxydant ou d'un produit alimentaire de soins de santé
CN112674351A (zh) 认知功能速度改善用的组合物
WO2016141774A1 (fr) Utilisations d'oligopeptide de ginseng de jilin dans la préparation de produit alimentaire ou de produit alimentaire de soins de santé pour améliorer et augmenter la fonction sexuelle
CN103478718B (zh) 提高人体内谷胱甘肽浓度的功能食品及其制备方法
JP2006199641A (ja) 鉄吸着性高分子物質及び鉄含有高分子物質ならびにこれらの製造方法
Aziz et al. Combating Metabolic Syndrome through Non-Pharmacological Strategies: A Literature Review: Combating Metabolic Syndrome
CN109805235B (zh) 一种辅助降四高的麦香复合多肽固体饮料、制备方法及用途
CN109157548B (zh) 一种具有抗疲劳和壮阳功能的组合物及制备方法
ES2311086T3 (es) Esporas de ganoderma lucidum para el tratamiento de lupus eritematosos sistemico (sle).
JP7090864B2 (ja) 組成物
JP6117963B2 (ja) ポリアミンを有効成分とする、組織の再生を促進するための組成物
JP5909173B2 (ja) ポリアミンを有効成分とする、組織の再生を促進するための組成物
TWI745609B (zh) 具抗氧化活性之組合物
TW201713357A (zh) 抗肥胖用組成物
US20220088106A1 (en) Composition comprising cudrania tricuspidate as effective component for alleviating, treating, or preventing muscular diseases, or improving muscule functions
RU2222997C1 (ru) Биологически активная добавка к пище

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16813479

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16813479

Country of ref document: EP

Kind code of ref document: A1